LBRX
LB Pharmaceuticals Inc Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$899.84M
P/E Ratio
—
EPS
$-3.13
Beta
—
52W High
$33.47
52W Low
$13.36
50-Day MA
$25.80
200-Day MA
$20.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.18M |
| Operating Margin | 0.00% |
| Return on Equity | -15.70% |
| Return on Assets | -10.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.91 |
| Price-to-Book | 2.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.68M |
| Float | $19.71M |
| % Insiders | 0.27% |
| % Institutions | 97.00% |
Historical Volatility
HV 10-Day
55.16%
HV 20-Day
68.39%
HV 30-Day
61.58%
HV 60-Day
58.29%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($44.00 target)
1
Strong Buy3
BuyData last updated: 4/29/2026